IRVING, Texas--(BUSINESS WIRE)--The introduction and prescribing of biosimilars could save billions of dollars in health care spend over the next decade. The barriers to realizing these savings center on physician familiarity and experience with the products, as well as regulatory and marketplace uncertainties. Novation’s Steven Lucio will address these barriers in his presentation, “Challenges to Ensuring Uptake of Biosimilars” at the Academy of Managed Care Pharmacy’s (AMCP) annual NEXUS 2015 conference, October 26-29 in Orlando.
A biosimilar is a copy of a therapeutic protein and is licensed based on a demonstration that it is highly similar to biological product, previously approved by FDA. There can be no clinically meaningful differences in terms of safety and effectiveness between the biosimilar and the originator’s reference product.
“It is an honor to be able to present at the AMCP’s conference on such an important topic. Biosimilars offer a tremendous potential for significant savings on life saving treatments for patients,” said Steven Lucio, senior director of Clinical Solutions and Pharmacy Program Development at Novation. “Pharmacists must take a leadership role in raising awareness of biosimilars through educating physicians on the utility of these products as alternatives to branded biologics and operationalizing the formulary evaluation of biosimilars for use in their hospitals.”
AMCP Nexus 2015 offers networking and educational sessions for managed care pharmacy professionals, individuals who manage and influence the pharmacy benefit and pharmaceutical care in today’s healthcare system. The conference is designed to provide profound insights and powerful tools to help find solutions for some of the toughest problems they face in improving outcomes and population health and reducing health care spending.
Lucio, Pharm.D., has over a decade of experience in clinical practice topics such as in improving medication safety, mitigating the impact of drug shortages, benchmarking pharmacy costs for key drug classes, evaluating the expense of high cost biologics and preparing for the future development of biosimilar medications. Lucio was lead author of the peer-reviewed article, “Biosimilars: Implications for health-system pharmacists” published in the November 15, 2013 issue of American Journal of Health-System Pharmacy. Additionally, he is an active speaker and panel moderator who has presented his insights on biosimilars more than a dozen times in the past year.
Novation is the nation’s leading health care services company, focused on revolutionizing operational performance for more than 100,000 members and affiliates of VHA Inc., UHC, Children’s Hospital Association and Provista LLC. Novation’s progressive approach to cost performance, data and intelligence, and integrated advisory solutions helps health care providers envision and advance new models of cost-effective, high-quality care. Headquartered in Irving, Texas, Novation is committed to the highest standards of ethical behavior and twice has been honored with the Ethisphere Institute’s coveted Ethics Inside® Certification, and has been named four years consecutively to Ethisphere’s World’s Most Ethical Companies list. To learn more about Novation, please visit novationco.com and follow @NovationNews on Twitter.